Updated on 2024/02/02

写真a

 
MARUYAMA Masato
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Associate Professor
Position
Associate Professor
External link

Degree

  • PhD ( Kyoto University )

Research Areas

  • Life Science / Clinical pharmacy

Professional Memberships

  • 日本薬剤学会 日本薬物動態学会 日本薬学会 日本癌学会

      More details

 

Papers

  • Development of Sustained Release System Based on High Water-Absorbable Gel Formation Using Croscarmellose Sodium, Alkaline Excipients and HPMC (ACSH SR System); Novel Application of Croscarmellose Sodium as a Gel Former

    Masato Gomi, Naoya Mizutani, Ryotaro Senoo, Noriaki Matsubara, Ayahisa Watanabe, Masato Maruyama, Go Kimura, Kazutaka Higaki

    Pharmaceutical Research   2023.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s11095-023-03630-w

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s11095-023-03630-w/fulltext.html

  • Possible Regulation of P-glycoprotein Function by Adrenergic Agonists II: Study with isolated rat jejunal sheets and Caco-2 cell monolayers

    Hironori Mukai, Masashi Takanashi, Ken-ichi Ogawara, Masato Maruyama, Kazutaka Higaki

    Journal of Pharmaceutical Sciences   2023.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.xphs.2023.11.010

    researchmap

  • Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport

    Keita Yamanouchi, Tomoki Ishimaru, Takuya Kakuno, Yuki Takemoto, Sho Kawatsu, Keiji Kondo, Masato Maruyama, Kazutaka Higaki

    European Journal of Pharmaceutics and Biopharmaceutics   187   141 - 155   2023.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.ejpb.2023.04.009

    researchmap

  • Establishment of a novel in vitro co-culture system of enteric neurons and Caco-2 cells for evaluating the effect of enteric nervous system on transepithelial transport of drugs

    Masato Maruyama, Minami Yoshikata, Mana Sakaguchi, Shizuka Wakushima, Kazutaka Higaki

    International Journal of Pharmaceutics   633   122617 - 122617   2023.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.ijpharm.2023.122617

    researchmap

  • Formation of a Stable Co-Amorphous System for a Brick Dust Molecule by Utilizing Sodium Taurocholate with High Glass Transition Temperature

    Shohei Aikawa, Hironori Tanaka, Hiroshi Ueda, Masato Maruyama, Kazutaka Higaki

    Pharmaceutics   15 ( 1 )   84 - 84   2022.12

     More details

    Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    Brick dust molecules are usually poorly soluble in water and lipoidal components, making it difficult to formulate them in dosage forms that provide efficient pharmacological effects. A co-amorphous system is an effective strategy to resolve these issues. However, their glass transition temperatures (Tg) are relatively lower than those of polymeric amorphous solid dispersions, suggesting the instability of the co-amorphous system. This study aimed to formulate a stable co-amorphous system for brick dust molecules by utilizing sodium taurocholate (NaTC) with a higher Tg. A novel neuropeptide Y5 receptor antagonist (AntiY5R) and NaTC with Tg of 155 °C were used as the brick dust model and coformer, respectively. Ball milling formed a co-amorphous system for AntiY5R and NaTC (AntiY5R-NaTC) at various molar ratios. Deviation from the theoretical Tg value and peak shifts in Fourier-transform infrared spectroscopy indicated intermolecular interactions between AntiY5R and NaTC. AntiY5R-NaTC at equal molar ratios resulting in an 8.5-fold increase in AntiY5R solubility over its crystalline form. The co-amorphous system remained amorphous for 1 month at 25 °C and 40 °C. These results suggest that the co-amorphous system formed by utilizing NaTC as a coformer could stably maintain the amorphous state and enhance the solubility of brick dust molecules.

    DOI: 10.3390/pharmaceutics15010084

    researchmap

  • Analysis of absorption-enhancing mechanisms for combinatorial use of spermine with sodium taurocholate in Caco-2 cells Reviewed

    Masato Maruyama, Yohei Nishida, Hironori Tanaka, Takako Minami, Ken-ichi Ogawara, Masateru Miyake, Yuta Takamura, Hiroki Kakuta, Kazutaka Higaki

    European Journal of Pharmaceutics and Biopharmaceutics   180   332 - 343   2022.11

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.ejpb.2022.10.020

    researchmap

  • Efficient Evaluation of In Vivo Performance in Human for Generic Formulation by Novel Dissolution-Absorption Prediction (DAP) Workflow Reviewed

    Motoki Onishi, Kozo Tagawa, Maiko Jiko, Kayo Koike, Masato Maruyama, Hidetoshi Hashizume, Kazuhide Imagaki, Kazutaka Higaki

    Pharmaceutical Research   39   2203 - 2216   2022.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s11095-022-03337-4

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s11095-022-03337-4/fulltext.html

  • Effect of Excessive Serotonin on Pharmacokinetics of Cephalexin after Oral Administration: Studies with Serotonin-Excessive Model Rats Reviewed

    Shun Nakashima, Takeharu Iwamoto, Masashi Takanashi, Ken-ichi Ogawara, Masato Maruyama, Kazutaka Higaki

    Pharmaceutical Research   2022.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s11095-022-03325-8

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s11095-022-03325-8/fulltext.html

  • Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion Reviewed

    Yusuke Sumimoto, Shinya Okawa, Tomoya Inoue, Kazufumi Masuda, Masato Maruyama, Kazutaka Higaki

    European Journal of Pharmaceutics and Biopharmaceutics   172   213 - 227   2022.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.ejpb.2022.02.002

    researchmap

  • Effect of Doxorubicin Release Rate From Polyethylene Glycol-Modified Liposome on Anti-tumor Activity in B16-BL6 Tumor-Bearing Mice Reviewed

    Masato Maruyama, Haruka Tojo, Keita Toi, Yusuke Ienaka, Kenji Hyodo, Hiroshi Kikuchi, Ken-ichi Ogawara, Kazutaka Higaki

    Journal of Pharmaceutical Sciences   111 ( 2 )   293 - 297   2022.2

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.xphs.2021.11.020

    researchmap

  • Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome Reviewed

    Takaya Minamisakamoto, Shuhei Nishiguchi, Kazuki Hashimoto, Ken-ichi Ogawara, Masato Maruyama, Kazutaka Higaki

    European Journal of Pharmaceutics and Biopharmaceutics   169   20 - 28   2021.12

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.ejpb.2021.08.013

    researchmap

  • Spermine with Sodium Taurocholate Enhances Pulmonary Absorption of Macromolecules in Rats. Reviewed International journal

    Masateru Miyake, Takanori Minami, Masato Maruyama, Tadashi Mukai, Kazutaka Higaki

    Journal of pharmaceutical sciences   110 ( 10 )   3464 - 3470   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The improvement effect of the combined use of spermine (SPM), a polyamine, with sodium taurocholate (STC) on the pulmonary drug absorption was investigated utilizing poorly absorbable drugs with various molecular sizes in rats. The pulmonary absorption of rebamipide, a low molecular but poorly absorbable drug after oral administration, was significantly improved by the combined use of SPM with STC (SPM-STC formulation), while poly- L-lysine did not show a significant change in rebamipide absorption from the lungs. Furthermore, the safety of the SPM-STC formulation for the lungs was assessed in rats by the histopathological study and any local toxicity was not observed while poly-L-lysine, a typical chemical causing the toxicity for the epithelial cells, provided several histopathological changes. In addition, the SPM-STC formulation significantly improved the pulmonary absorption of fluorescein isothiocyanate dextran 4 (FD-4, Mw ca 4000) and interferon-α (IFN-α, Mw ca 25,000) as well. Our present results clearly indicated that the SPM-STC formulation significantly improved the pulmonary absorption of poorly absorbable small and large molecular drugs without any harmful effects on the lungs. Therefore, the SPM-STC formulation would be a useful one for the pulmonary absorption of drugs, specifically macromolecular ones, which are very difficult to be absorbed after oral administration.

    DOI: 10.1016/j.xphs.2021.06.015

    PubMed

    researchmap

  • Possible Regulation of P-glycoprotein Function by Adrenergic Agonists in a Vascular-luminal Perfused Preparation of Small Intestine Reviewed

    Hironori Mukai, Masashi Takanashi, Ken-ichi Ogawara, Masato Maruyama, Kazutaka Higaki

    Journal of Pharmaceutical Sciences   2021.9

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.xphs.2021.09.014

    researchmap

  • PC3-Secreted Microprotein Is Expressed in Glioblastoma Stem-Like Cells and Human Glioma Tissues. Reviewed

    Masato Maruyama, Yousuke Nakano, Takuya Nishimura, Ryoichi Iwata, Satoshi Matsuda, Mikio Hayashi, Yuki Nakai, Masahiro Nonaka, Tetsuo Sugimoto

    Biological & pharmaceutical bulletin   44 ( 7 )   910 - 919   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumor with a high recurrence rate. Despite multimodal therapy including surgical resection, chemotherapy, and radiotherapy, the median survival time after the initial diagnosis of GBM is approximately 14 months. Since cancer stem cells (CSCs) are considered the leading cause of cancer recurrence, glioblastoma stem cell-targeted therapy is a promising strategy for the treatment of GBM. However, because CSC heterogeneity has been implicated in the difficulties of CSC-target therapy, more in-depth knowledge of CSC biology is still required to develop novel therapies. In this study, we established single cell-derived tumorspheres from human glioblastoma U87MG cells. One of these tumorspheres, P4E8 clone, showed CSC-like phenotypes, such as self-renewal capacity, expression of CSC markers, resistance to anti-cancer agents, and in vivo tumorigenicity. Therefore, we used P4E8 cells as a cell-based model of glioblastoma stem cells (GSCs). Gene expression analysis using microarray indicated that the most highly expressed genes in P4E8 cells compared to the parental U87MG were PC3-secreted microprotein (MSMP). Furthermore, MSMP was expressed in patient-derived GSCs and human glioma tissues at the protein level, implying that MSMP might contribute to glioma development and progression.

    DOI: 10.1248/bpb.b20-00868

    PubMed

    researchmap

  • Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation. Reviewed International journal

    Shinya Okawa, Yusuke Sumimoto, Kazufumi Masuda, Ken-Ichi Ogawara, Masato Maruyama, Kazutaka Higaki

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences   159   105721 - 105721   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Among drugs in development and/or in market, there are poorly water-soluble and poorly lipid-soluble compounds. Rebamipide, classified into BCS class IV, is one of those drugs which provide very low bioavailability and/or the difficulty of formulation for oral administration. Because of its low solubility in available lipoidal excipients, it was impossible to prepare an adequate SNEDDS formulation of rebamipide. Then, we tried to increase the solubility of rebamipide in lipoidal excipients for preparing a more practical SNEDDS formulation by making the complex with its counter ion, tetrabutylphosphonium hydroxide (TBPOH) or NaOH. Rebamipide concentration in ethanol was proportionally increased with the increment of TBPOH or NaOH added, indicating that the formation of complex with a counter ion should contribute to the solubilization of rebamipide in ethanol. Both Rebamipide-TBPOH complex (Reb-TBPOH) and Rebamipide-NaOH complex (Reb-NaOH) obtained by lyophilization showed no endothermic peak in DSC and no diffraction peak in XRPD, suggesting that the solid state of both complexes should be amorphous. Reb-TBPOH maintained the dissolution of rebamipide in SNEDDS vehicle (Capryol 90:Cremophor EL:Transcutol P = 4:3:3) at 20 mg/g at least for 28 days, while Reb-NaOH did it at 10 mg/g. In vitro dissolution study showed that Reb-TBPOH SNEDDS and Reb-NaOH SNEDDS containing rebamipide at 10 mg/g maintained the complete dissolution of rebamipide in FaSSIF (intestinal luminal condition). In the gastric luminal condition (pH3.9 acetate buffer), the high concentration, close to the complete dissolution, was transiently observed and quickly decreased to one-sixth of the maximum, but it was still around 70 times higher than that of the crystalline powder. The additional utilization of Eudragit EPO for SNEDDS preparations of both complexes successfully maintained the high concentrations of rebamipide in the gastric luminal condition. In vivo oral absorption studies clearly indicated that SNEDDS preparations utilizing Reb-counter ion complex successfully improved rebamipide absorption.

    DOI: 10.1016/j.ejps.2021.105721

    PubMed

    researchmap

  • BATTLE: Genetically Engineered Strategies for Split-Tunable Allocation of Multiple Transgenes in the Nervous System. Reviewed International journal

    Keigo Kohara, Akitoshi Inoue, Yousuke Nakano, Hirokazu Hirai, Takuya Kobayashi, Masato Maruyama, Ryosuke Baba, Chiho Kawashima

    iScience   23 ( 6 )   101248 - 101248   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Elucidating fine architectures and functions of cellular and synaptic connections requires development of new flexible methods. Here, we created a concept called the "battle of transgenes," based on which we generated strategies using genetically engineered battles of multiple recombinases. The strategies enabled split-tunable allocation of multiple transgenes. We demonstrated the versatility of these strategies and technologies in inducing strong and multi-sparse allocations of multiple transgenes. Furthermore, the combination of our transgenic strategy and expansion microscopy enabled three-dimensional high-resolution imaging of whole synaptic structures in the hippocampus with simultaneous visualizations of endogenous synaptic proteins. These strategies and technologies based on the battle of genes may accelerate the analysis of whole synaptic and cellular connections in diverse life science fields.

    DOI: 10.1016/j.isci.2020.101248

    PubMed

    researchmap

  • ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma. Reviewed International journal

    Ryoichi Iwata, Joo Hyoung Lee, Mikio Hayashi, Umberto Dianzani, Kohei Ofune, Masato Maruyama, Souichi Oe, Tomoki Ito, Tetsuo Hashiba, Kunikazu Yoshimura, Masahiro Nonaka, Yosuke Nakano, Lyse Norian, Ichiro Nakano, Akio Asai

    Neuro-oncology   22 ( 3 )   333 - 344   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Targeting immune checkpoint proteins has recently gained substantial attention due to the dramatic success of this strategy in clinical trials for some cancers. Inducible T-cell co-stimulator ligand (ICOSLG) is a member of the B7 family of immune regulatory ligands, expression of which in cancer is implicated in disease progression due to regulation of antitumor adaptive immunity. Although aberrant ICOSLG expression has been reported in glioma cells, the underlying mechanisms that promote glioblastoma (GBM) progression remain elusive. METHODS: Here, we investigated a causal role for ICOSLG in GBM progression by analyzing ICOSLG expression in both human glioma tissues and patient-derived GBM sphere cells (GSCs). We further examined its immune modulatory effects and the underlying molecular mechanisms. RESULTS: Bioinformatics analysis and GBM tissue microarray showed that upregulation of ICOSLG expression was associated with poor prognosis in patients with GBM. ICOSLG expression was upregulated preferentially in mesenchymal GSCs but not in proneural GSCs in a tumor necrosis factor-α/nuclear factor-kappaB-dependent manner. Furthermore, ICOSLG expression by mesenchymal GSCs promoted expansion of T cells that produced interleukin-10. Knockdown of the gene encoding ICOSLG markedly reduced GBM tumor growth in immune competent mice, with a concomitant downregulation of interleukin-10 levels in the tumor microenvironment. CONCLUSIONS: Inhibition of the ICOSLG-inducible co-stimulator axis in GBM may provide a promising immunotherapeutic approach for suppressing a subset of GBM with an elevated mesenchymal signature.

    DOI: 10.1093/neuonc/noz204

    PubMed

    researchmap

  • The involvement of cancer stem cells in brain metastatic process Invited Reviewed

    岩田亮一, 丸山正人, 大舟晃平, 中野洋輔, 大江総一, 林美樹夫, 吉村晋一, 埜中正博, 淺井昭雄

    Cytometry Research (Web)   28 ( 1 )   2018

  • Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor Reviewed

    Ryoichi Iwata, Masato Maruyama, Tomoki Ito, Yosuke Nakano, Yonehiro Kanemura, Taro Koike, Souichi Oe, Kunikazu Yoshimura, Masahiro Nonaka, Shosaku Nomura, Tetsuo Sugimoto, Hisao Yamada, Akio Asai

    MEDICAL MOLECULAR MORPHOLOGY   50 ( 4 )   211 - 219   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    Neuroendocrine tumors are rare, and little is known about the existence of cancer stem cells in this disease. Identification of the tumorigenic population will contribute to the development of effective therapies targeting neuroendocrine tumors. Surgically resected brain metastases from a primary neuroendocrine tumor of unknown origin were dissociated and cultured in serum-free neurosphere medium. Stem cell properties, including self-renewal, differentiation potential, and stem cell marker expression, were examined. Tumor formation was evaluated using intracranial xenograft models. The effect of temozolomide was measured in vitro by cell viability assays. We established the neuroendocrine tumor sphere cell line ANI-27S, which displayed stable exponential growth, virtually unlimited expansion in vitro, and expression of stem-cell markers such as CD133, nestin, Sox2, and aldehyde dehydrogenase. FBS-induced differentiation decreased Sox2 and nestin expression. On the basis of real-time PCR, ANI-27S cells expressed the neuroendocrine markers synaptophysin and chromogranin A. Intracranial xenotransplanted brain tumors recapitulated the original patient tumor and temozolomide exhibited cytotoxic effects on tumor sphere cells. For the first time, we demonstrated the presence of a sphere-forming, stem cell-like population in brain metastases from a primary neuroendocrine tumor. We also demonstrated the potential therapeutic effects of temozolomide for this disease.

    DOI: 10.1007/s00795-017-0160-0

    Web of Science

    PubMed

    researchmap

  • Overview and assessment of the histochemical methods and reagents for the detection of beta-galactosidase activity in transgenic animals Reviewed

    Stefan Trifonov, Yuji Yamashita, Masahiko Kase, Masato Maruyama, Tetsuo Sugimoto

    ANATOMICAL SCIENCE INTERNATIONAL   91 ( 1 )   56 - 67   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    Bacterial beta-galactosidase is one of the most widely used reporter genes in experiments involving transgenic and knockout animals. In this review we discuss the current histochemical methods and available reagents to detect beta-galactosidase activity. Different substrates are available, but the most commonly used is X-gal in combination with potassium ferri-and ferro-cyanide. The reaction produces a characteristic blue precipitate in the cells expressing beta-galactosidase, and despite its efficiency in stainingwhole embryos, its detection on thin tissue sections is difficult. Salmon-gal is another substrate, which in combination with ferric and ferrous ions gives a reddish-pink precipitate. Its sensitivity for staining tissue sections is similar to that of X-gal. Combining X-gal or Salmon-gal with tetrazolium salts provides a faster and more sensitive reaction than traditional beta-galactosidase histochemistry. Here, we compare the traditional beta-galactosidase assay and the combination of X-gal or Salmon-gal with three tetrazolium salts: nitroblue tetrazolium, tetranitroblue tetrazolium and iodonitrotetrazolium. Based on an assessment of the sensitivity and specificity of the different combinations of substrates, we are proposing an optimized and enhanced method for beta-galactosidase detection in histological sections of the transgenic mouse brain. Optimal staining was obtained with X-gal in combination with nitroblue tetrazolium, which provides a faster and more specific staining than the traditional X-gal combination with potassium ferri-and ferro-cyanide. We recommend the X-gal/nitroblue tetrazolium staining mixture as the first choice for the detection of beta-galactosidase activity on histological sections. When faster results are needed, Salmon-gal/nitroblue tetrazolium should be considered as an alternative, while maintaining acceptable levels of noise.

    DOI: 10.1007/s12565-015-0300-3

    Web of Science

    researchmap

  • Glutamic acid decarboxylase 1 alternative splicing isoforms: characterization, expression and quantification in the mouse brain Reviewed

    Stefan Trifonov, Yuji Yamashita, Masahiko Kase, Masato Maruyama, Tetsuo Sugimoto

    BMC NEUROSCIENCE   15 ( 1 )   Article No. 114   2014.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BIOMED CENTRAL LTD  

    Background: GABA has important functions in brain plasticity related processes like memory, learning, locomotion and during the development of the nervous system. It is synthesized by the glutamic acid decarboxylase (GAD). There are two isoforms of GAD, GAD1 and GAD2, which are encoded by different genes. During embryonic development the transcription of GAD1 mRNA is regulated by alternative splicing and several alternative transcripts were distinguished in human, mouse and rat. Despite the fact that the structure of GAD1 gene has been extensively studied, knowledge of its exact structural organization, alternative promoter usage and splicing have remained incomplete.
    Results: In the present study we report the identification and characterization of novel GAD1 splicing isoforms (GenBank: KM102984, KM102985) by analyzing genomic and mRNA sequence data using bioinformatics, cloning and sequencing. Ten mRNA isoforms are generated from GAD1 gene locus by the combined actions of utilizing different promoters and alternative splicing of the coding exons. Using RT-PCR we found that GAD1 isoforms share similar pattern of expression in different mouse tissues and are expressed early during development. Quantitative RT-PCR was used to investigate the expression of GAD1 isoforms and GAD2 in olfactory bulb, cortex, medial and lateral striatum, hippocampus and cerebellum of adult mouse. Olfactory bulb showed the highest expression of GAD1 transcripts. Isoforms 1/2 are the most abundant forms. Their expression is significantly higher in the lateral compared to the medial striatum. Isoforms 3/4, 5/6, 7/8 and 9/10 are barely detectable in all investigated regions except of the high expression in olfactory bulb. When comparing GAD1 expression with GAD2 we found that Isoforms 1/2 are the predominant isoforms. In situ hybridization confirmed the predominant expression of Isoforms 7/8 and 9/10 in the olfactory bulb and revealed their weak expression in hippocampus, cerebellum and some other areas known to express GAD1.
    Conclusions: Generation of ten splicing isoforms of GAD1 was described including two so far uncharacterized transcripts. GAD1 splicing isoforms producing the shorter, enzymatically inactive GAD25 protein are expressed at very low level in adult mouse brain except in the olfactory bulb that is associated with neurogenesis and synaptic plasticity even during adulthood.

    DOI: 10.1186/1471-2202-15-114

    Web of Science

    researchmap

  • Lineage-specific purification of neural stem/progenitor cells from differentiated mouse induced pluripotent stem cells Reviewed

    Masato Maruyama, Yuji Yamashita, Masahiko Kase, Stefan Trifonov, Tetsuo Sugimoto

    Stem Cells Translational Medicine   2 ( 6 )   420 - 433   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:John Wiley and Sons Ltd  

    Since induced pluripotent stem (iPS) cells have differentiation potential into all three germ layer-derived tissues, efficient purification of target cells is required in many fields of iPS research. One useful strategy is isolation of desired cells from differentiated iPS cells by lineage-specific expression of a drug-resistance gene, followed by drug selection. With this strategy, we purified neural stem/ progenitor cells (NSCs), a good candidate source for regenerative therapy, from differentiated mouse iPS cells. We constructed a bicistronic expression vector simultaneously expressing blastici-din S resistance gene and DsRed under the control of tandem enhancer of a 257-base pair region of nestin second intron, an NSC-specific enhancer. This construct was efficiently inserted into the iPS genome by piggyBac transposon-mediated gene transfer, and the established subclone was differentiated into NSCs in the presence or absence of blasticidin S. Consequently, incubation with blas-ticidin S led to purification of NSCs from differentiated iPS cells. Our results suggest that a lineage-specific drug selection strategy is useful for purification of NSCs from differentiated iPS cells and that this strategy can be applied for the purification of other cell types. © AlphaMed Press 2013.

    DOI: 10.5966/sctm.2012-0139

    Scopus

    researchmap

  • Aminopeptidase Q/Laeverin Reviewed

    Akira Hattori, Masato Maruyama, Hiroshi Fujiwara, Masafumi Tsujimoto

    Handbook of Proteolytic Enzymes   1   442 - 444   2013

     More details

    Language:English   Publishing type:Part of collection (book)   Publisher:Elsevier Ltd  

    DOI: 10.1016/B978-0-12-382219-2.00089-2

    Scopus

    researchmap

  • 中枢聴覚系のコリン線維とムスカリン性受容体(Cholinergic Fibers and Muscarinic Receptors in the Central Auditory System) Reviewed

    濱田 聡子, ステファン・トリフォノフ, 宝谷 剛志, 加瀬 政彦, 山下 雄司, 馬場 一泰, 清水 順一, 丸山 正人, 友田 幸一, 山下 敏夫, 杉本 哲夫

    関西医科大学雑誌   63   7-9 - 9   2012.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:関西医科大学医学会  

    マウス脳を用いて、聴覚上行路各部位におけるコリン線維とムスカリン性受容体(m2、m3タイプ)の発現分布密度について測定した。その結果、聴覚上行路諸核において、これらコリン線維・受容体を介する情報転達・変換が、聴覚の伝達に一定の意義を有していることが示唆された。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J00279&link_issn=&doc_id=20121218420002&doc_link_id=10.5361%2Fjkmu.63.7&url=https%3A%2F%2Fdoi.org%2F10.5361%2Fjkmu.63.7&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Laeverin/aminopeptidase Q induces trophoblast invasion during human early placentation Reviewed

    Akihito Horie, Hiroshi Fujiwara, Yukiyasu Sato, Koh Suginami, Hisanori Matsumoto, Masato Maruyama, Ikuo Konishi, Akira Hattori

    HUMAN REPRODUCTION   27 ( 5 )   1267 - 1276   2012.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OXFORD UNIV PRESS  

    In primate placenta, extravillous trophoblast (EVT) invades maternal tissue in temporally- and spatially-regulated fashions. We previously identified a novel placenta-specific cell-surface aminopeptidase, laeverin/aminopeptidase Q, which is expressed on EVT-lineage cells in the fetal membrane. Laeverin possesses a peptide-binding site that is evolutionally unique to primates, suggesting possible involvement of laeverin in a primate-specific phenomenon during placentation. Thus, this study was designed to elucidate the molecular characteristics and physiological roles of laeverin in human EVT.
    Placental tissues of various developmental stages were subjected to immunostaining and western blotting. Effects of siRNA and a soluble form of recombinant laeverin on EVT cells isolated from primary villous explant cultures were examined using Matrigel invasion assays and cell proliferation assays.
    Laeverin was specifically immunolocalized to HLA-G-positive EVT in placentas from early and term pregnancy. In primary villous explant cultures, laeverin expression was induced on the cell surface of the outgrowing EVT. In western blotting, laeverin protein was detected as two distinct bands at 130 and 160 kDa along with a broad band ranging from 200 to 270 kDa. De-glycosylation treatment showed that these native laeverin isotypes are N-linked glycoproteins sharing a common 115-kDa core protein. In invasion assays, the reduction of laeverin expression by siRNA suppressed migration of the isolated EVT, while the soluble form of recombinant laeverin enhanced its migration.
    Laeverin is a specific cell-surface marker for human EVT and plays a regulatory role in EVT migration.

    DOI: 10.1093/humrep/des068

    Web of Science

    researchmap

  • Lateral regions of the rodent striatum reveal elevated glutamate decarboxylase 1 mRNA expression in medium-sized projection neurons Reviewed

    Stefan Trifonov, Takeshi Houtani, Masahiko Kase, Kazunori Toida, Masato Maruyama, Yuji Yamashita, Jun-Ichi Shimizu, Tetsuo Sugimoto

    EUROPEAN JOURNAL OF NEUROSCIENCE   35 ( 5 )   711 - 722   2012.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    The GABA-synthesizing enzymes glutamate decarboxylase (GAD)1 and GAD2 are universally contained in GABAergic neurons in the central nervous system of the mouse and rat. The two isoforms are almost identically expressed throughout the brain and spinal cord. By using in situ hybridization, we found that the mouse lateral striatum concentrates medium-sized projection neurons with high-level expression of GAD1, but not of GAD2, mRNA. This was confirmed with several types of riboprobe, including those directed to the 5'-noncoding, 3'-noncoding and coding regions. Immunohistochemical localization of GAD1 also revealed predominant localization of the enzyme in the same striatal region. The lateral region of the mouse striatum, harboring such neurons, is ovoid in shape and extends between interaural +4.8 and +2.8, and at lateral 2.8 and dorsoventral 2.0. This intriguing region corresponds to the area that receives afferent inputs from the primary motor and sensory cortex that are presumably related to mouth and forelimb representations. The lateral striatum is included in the basal ganglia-thalamocortical loop, and is most vulnerable to various noxious stimuli in the neurodegeneration processes involving the basal ganglia. We have confirmed elevated expression of GAD1 mRNA, but not of GAD2 mRNA, also in the rat lateral striatum. Image analysis favored the view that the regional increase is caused by elevated cellular expression, and that the greatest number of medium-sized spiny neurons were positive for GAD1 mRNA. The GAD1 mRNA distribution in the mouse lateral striatum partially resembled those of GPR155 and cannabinoid receptor type 1 mRNAs, suggesting functional cooperation in some neurons.

    DOI: 10.1111/j.1460-9568.2012.08001.x

    Web of Science

    researchmap

  • Histological determination of the areas enriched in cholinergic terminals and m2 and m3 muscarinic receptors in the mouse central auditory system Reviewed

    Hamada S, Houtani T, Trifonov S, Kase M, Maruyama M, Shimizu J, Yamashita T, Tomoda K, Sugimoto T

    The Anatomical Record   293 ( 8 )   1393-1399   2010.8

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ar.21186

    researchmap

  • Histological Determination of the Areas Enriched in Cholinergic Terminals and m2 and m3 Muscarinic Receptors in the Mouse Central Auditory System Reviewed

    Satoko Hamada, Takeshi Houtani, Stefan Trifonov, Masahiko Kase, Masato Maruyama, Jun-Ichi Shimizu, Toshio Yamashita, Koichi Tomoda, Tetsuo Sugimoto

    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY   293 ( 8 )   1393 - 1399   2010.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-LISS  

    Cholinergic projections to auditory system are vital for coupling arousal with sound processing. Systematic search with in situ hybridization and immunohistochemistry indicated that the ventral nucleus of the medial geniculate body and the nucleus of the brachium of the inferior colliculus constituted cholinergic synaptic sites in the brainstem auditory system, containing a significant number of cholinergic axon terminals and m2 receptor-expressing cell bodies. Anat Rec, 293:1393-1399, 2010. (C) 2010 Wiley-Liss, Inc.

    DOI: 10.1002/ar.21186

    Web of Science

    researchmap

  • GPR155: Gene organization, multiple mRNA splice variants and expression in mouse central nervous system Reviewed

    Stefan Trifonov, Takeshi Houtani, Jun-ichi Shimizu, Satoko Hamada, Masahiko Kase, Masato Maruyama, Tetsuo Sugimoto

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   398 ( 1 )   19 - 25   2010.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Emerging evidence suggests that GPR155, an integral membrane protein related to G-protein coupled receptors, has specific roles in Huntington disease and autism spectrum disorders. This study reports the structural organization of mouse GPR155 gene and the generation of five variants (Variants 1-5) of GPR155 mRNA, including so far unknown four variants. Further, it presents the level of expression of GPR155 mRNA in different mouse tissues. The mRNAs for GPR155 are widely expressed in adult mouse tissues and during development. In situ hybridization was used to determine the distribution of GPR155 in mouse brain. The GPR155 mRNAs are widely distributed in forebrain regions and have more restricted distribution in the midbrain and hindbrain regions. The highest level of expression was in the lateral part of striatum and hippocampus. The expression pattern of GPR155 mRNAs in mouse striatum was very similar to that of cannabinoid receptor type 1. The predicted protein secondary structure indicated that GPR155 is a 17-TM protein, and Variant 1 and Variant 5 proteins have an intracellular, conserved DEP domain near the C-terminal. (C) 2010 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2010.05.162

    Web of Science

    researchmap

  • Histidine 379 of Human Laeverin/Aminopeptidase Q, a Nonconserved Residue within the Exopeptidase Motif, Defines Its Distinctive Enzymatic Properties Reviewed

    Masato Maruyama, Naomi Arisaka, Yoshikuni Goto, Yosuke Ohsawa, Hideshi Inoue, Hiroshi Fujiwara, Akira Hattori, Masafumi Tsujimoto

    JOURNAL OF BIOLOGICAL CHEMISTRY   284 ( 50 )   34692 - 34702   2009.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    Human laeverin/aminopeptidase Q (LVRN/APQ) is a novel member of the M1 family of zinc aminopeptidases and is specifically expressed on the cell surface of human extravillous trophoblasts. Multiple sequence alignment of human M1 aminopeptidase revealed that the first Gly residue within the conserved exopeptidase motif of the M1 family, GXMEN motif, is uniquely substituted for His in human LVRN/APQ. In this study, we evaluated the roles of nonconserved His(379), comprising the exopeptidase motif in the enzymatic properties of human LVRN/APQ. We revealed that the substitution of His(379) with Gly caused significant changes in substrate specificity both toward fluorogenic substrates and natural peptide hormones. In addition, the susceptibilities of bestatin, a sensitive inhibitor for human LVRN/APQ, and natural inhibitory peptides were decreased in the H379G mutant. A molecular model suggested a conformational difference between wild-type and H379G human LVRN/APQs. These results indicate that His(379) of the enzyme plays essential roles in its distinctive enzymatic properties and contributes to maintaining the appropriate structure of the catalytic cavity of the enzyme. Our data may bring new insight into the biological significance of the unique exopeptidase motif of LVRN/APQ obtained during the evolution of primates.

    DOI: 10.1074/jbc.M109.066712

    Web of Science

    researchmap

  • 中枢聴覚路におけるコリン線維とムスカリン性受容体サブタイプ発現の解析 Reviewed

    濱田聡子, 宝谷剛志, Trifonov Stefan, 丸山正人, 加瀬政彦, 堤 俊之, 杉本哲夫, 友田幸一, 山下敏夫

    頭頸部自律神経   23   72-73 - 73   2009.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:耳鼻咽喉科ニューロサイエンス研究会  

    マウスを用い、ムスカリン性アセチルコリン受容体のサブタイプm2(抑制性神経伝達受容体)、およびm3(興奮性神経伝達受容体)の発現を、コリン性入力線維(VAChT)の局在と比較した。VAChT免疫陽性瘤状線維は脚橋被蓋核、三叉神経運動核、顔面神経核、舌下神経核、迷走神経背側運動核において発現密度高値を示した。m2ムスカリン受容体mRNA(m2)も同様であったが、m3では発現細胞はほとんどなかった。VAChT免疫陽性線維は大脳皮質聴覚野、内側膝状体、下丘腕核、蝸牛神経腹側核において発現密度が高かった。m2は大脳皮質聴覚野、内側膝状体、下丘腕核・背側核・外側核、蝸牛神経背側核において発現密度が高かった。m3は大脳皮質聴覚野内側膝状体、下丘背側核、蝸牛神経背側核において発現密度が高かった。中枢聴覚路におけるVAChT、およびコリン受容体発現細胞におけるm2、m3の受容体の発現分布が判明し、聴覚障害に対するムスカリン受容体サブタイプに特異的な薬物の臨床応用が考えられた。

    researchmap

  • Effects of Methyl-beta-cyclodextrin Treatment on Secretion Profile of Interferon-beta and Zonula Occuludin-1 Architecture in Madin-Darby Canine Kidney Cell Monolayers Reviewed

    Masato Maruyama, Kayo Ishida, Yoshihiko Watanabe, Makiya Nishikawa, Yoshinobu Takakura

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   32 ( 5 )   910 - 915   2009.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PHARMACEUTICAL SOC JAPAN  

    The interferon (IFN) is a paradigm of secretory protein. However, it has been poorly understood how its secretion is regulated in polarized epithelial cells. Recently, we had shown that exogenous IFNs transiently expressed in polarized monolayers were predominantly secreted to the side on which gene transfection had been performed, while stably expressed IFNs were secreted almost equally to the both cell sides. Since those modes of secretion did not affect each other, epithelial cell layers seemed to have at least two protein sorting/secretion pathways, one for transient expression and the other for stable expression, for identical secretory proteins. Furthermore, this dual secretion profile seemed to be mediated by distinct post-trans Golgi network vesicles, suggesting the involvement of lipid rafts in the sorting multiplicity. To address this issue, here we studied the effects of cholesterol depletion with methyl-beta-cyclodextrin (M beta CD) on the secretion profile of IFN-beta exogenously expressed in Madin-Darby canine kidney (MDCK) cells. The M beta CD-treatment, however, did not affect the profile in either transient or stable expression, although the architecture of zonula occuludin-1, which links to the tight junction, was substantially disrupted by the treatment. Further analysis of Triton X-100-insoluble cell extracts by sucrose density centrifugation demonstrated that IFN-beta was not apparently associated with lipid rafts in either transient or stable expression. These results suggest that lipid rafts may not be crucially involved in the regulation of secretion polarity of IFN-beta in the epithelial cells.

    Web of Science

    researchmap

  • IN SITU HYBRIDIZATION STUDY OF THE DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE mRNA AND ITS SPLICE VARIANTS IN THE MOUSE BRAIN AND SPINAL CORD Reviewed

    S. Trifonov, T. Houtani, S. Hamada, M. Kase, M. Maruyama, T. Sugimoto

    NEUROSCIENCE   159 ( 1 )   344 - 357   2009.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PERGAMON-ELSEVIER SCIENCE LTD  

    Choline acetyltransferase is the enzyme that catalyzes the biosynthesis of the neurotransmitter acetylcholine. Seven types of mRNA for choline acetyltransferase that differ in the 5'-noncoding region are transcribed from the cholinergic gene locus from different promoter regions and produced by alternative splicing in the mouse. Digoxigenin-labeled riboprobes and in situ hybridization histochemistry were used to investigate the expression of N1, R1, R2, R3, R4 and total choline acetyltransferase mRNA in the mouse CNS. The relative levels of choline acetyltransferase transcripts differed dramatically in distinct subdivisions of the mature cholinergic nervous system. Neurons hybridizing with antisense riboprobes for all of the five investigated splice variants (R1, R2, R3, R4 and N1) as well as those hybridizing with riboprobe for the common protein-coding region were found in a number of expected regions in the CNS. They include the basal forebrain, striatum, pontomesencephalic tegmentum, motor and autonomic nuclei of the brainstem, and spinal cord. Neurons with a moderate to very high level of expression of R1 and R2 splice variants were distributed in both the forebrain and brainstem nuclei. On the other hand, R3, R4 and N1 splice variants revealed a moderate to high level of expression in the brainstem motor and autonomic nuclei and ventral and lateral horns of the spinal cord compared to a low expression level in forebrain cholinergic structures. No expression of the N1, R1, R2, R3 and R4 splice variants was detectable in the neurons of the cerebral cortex, hippocampus and medial habenular nucleus. With the riboprobe for the common protein-coding region, the neurons of the medial habenular nucleus could be labeled at high level, while intrinsic cortical neurons were labeled at low level. Hippocampus revealed no significant hybridization for total choline acetyltransferase mRNA. These findings strongly suggested that: (1) R1 and R2 were the major splice variants expressed in the neurons of forebrain nuclei; (2) R1, R2, R3, R4 and N1 splice variants were almost equally expressed in the brainstem motor and autonomic nuclei and ventral and lateral horns of the spinal cord; (3) inferring from a paucity of other isoforms, M type choline acetyltransferase mRNA is a splice variant predominantly expressed in the cerebral cortex and medial habenular nucleus. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.neuroscience.2008.12.054

    Web of Science

    researchmap

  • Biochemical and enzymatic properties of the M1 family of aminopeptidases involved in the regulation of blood pressure Reviewed

    Masafumi Tsujimoto, Yoshikuni Goto, Masato Maruyama, Akira Hattori

    HEART FAILURE REVIEWS   13 ( 3 )   285 - 291   2008.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    It is becoming evident that several aminopeptidases belonging to the M1 family such as aminopeptidase A (APA), placental leucine aminopeptidase (P-LAP), and adipocyte-derived leucine aminopeptidase (A-LAP) play important roles in the regulation of blood pressure under both the physiological and pathological conditions. They share HEXXH(X)(18)E zinc-binding and GAMEN motifs essential for enzymatic activities. In this review, the current situation regarding the biochemical characteristics of these enzymes including enzymatic properties and modes of action is summarized.

    DOI: 10.1007/s10741-007-9064-8

    Web of Science

    researchmap

  • Laeverin/aminopeptidase Q, a novel bestatin-sensitive leucine aminopeptidase belonging to the M1 family of aminopeptidases Reviewed

    Masato Maruyama, Akira Hattori, Yoshikuni Goto, Masamichi Ueda, Michiyuki Maeda, Hiroshi Fujiwara, Masafumi Tsujimoto

    JOURNAL OF BIOLOGICAL CHEMISTRY   282 ( 28 )   20088 - 20096   2007.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC  

    Laeverin/aminopeptidase Q (APQ) is a cell surface protein specifically expressed on human embryo-derived extravillous trophoblasts that invades the uterus during placentation. The cDNA cloning of Laeverin/APQ revealed that the sequence encodes a protein with 990 amino acid residues, and Laeverin/APQ contains the HEXXHX18E gluzincin motif, which is characteristic of the M1 family of aminopeptidases, although the exopeptidase motif of the family, GAMEN, is uniquely substituted for the HAMEN sequence. In this study, we expressed a recombinant human Laeverin/APQ using a baculovirus expression system, purified to homogeneity, and characterized its enzymatic properties. It was found that Laeverin/APQ had a broad substrate specificity toward synthetic substrate, although it showed a preference for Leu-4-methylcoumaryl-7-amide. Searching natural substrates, we found that Laeverin/ APQ was able to cleave the N-terminal amino acid of several peptides such as angiotensin III, kisspeptin-10, and endokinin C, which are abundantly expressed in the placenta. In contrast to the case with other M1 aminopeptidases, bestatin inhibited the aminopeptidase activity of Laeverin/ APQ much more effectively than other known aminopeptidase inhibitors. These results indicate that Laeverin/ APQis a novel bestatin-sensitive leucine aminopeptidase and suggest that the enzyme plays important roles in human placentation by regulating biological activity of key peptides at the embryo- maternal interface.

    DOI: 10.1074/jbc.M702650200

    Web of Science

    researchmap

  • Cholesterol is required for the polarized secretion of erythropoietin in Madin-Darby canine kidney cells Reviewed

    M Maruyama, M Kishimoto, K Ishida, Y Watanabe, M Nishikawa, S Masuda, R Sasaki, Y Takakura

    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS   438 ( 2 )   174 - 181   2005.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    It has already been reported that stably expressed exogenous human wild-type EPO (wtEPO) is preferentially secreted to the apical side and one of the three N-linked carbohydrate chains critically acts as an apical sorting determinant in Madin-Darby canine kidney (MDCK) cells. It has been suggested that lipid rafts are involved in the apical sorting of membrane and secretory proteins. To investigate the involvement of lipid rafts in the apical sorting of wtEPO, we examined the effect of cholesterol depletion with methyl-beta-cyclodextrin on the secretion polarity of EPO and analyzed Triton X-100 insoluble cell extracts by sucrose density gradients centrifugation in MDCK cells. We found that wtEPO was shifted in non-polarized direction by cholesterol depletion. Most of the wtEPO was not detectable in the raft fractions by sucrose density gradients centrifugation analysis. These results indicate that apical secretion of EPO involves a cholesterol-dependent mechanism probably not involving lipid rafts. (c) 2005 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.abb.2005.04.005

    Web of Science

    researchmap

  • Secretion mode and subcellular localization of human interferon-beta exogenously expressed in porcine renal epithelial LLC-PK1 cells Reviewed

    T Nishio, M Maruyama, T Yoshida, Y Watanabe, M Nishikawa, Y Takakura

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   27 ( 10 )   1653 - 1655   2004.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PHARMACEUTICAL SOC JAPAN  

    We have investigated the secretion polarity of human interferon-beta (HuIFN-beta) exogenously expressed in the porcine renal proximal tubule cell line, LLC-PK1,. In these cells, stably expressed HuIFN-beta was secreted to the apical and basolateral sides. However, when transiently expressed by apical lipofection, HuIFN-beta was secreted to both cell sides, while basolateral-preferential secretion was seen for basal transfection. Confocal imaging using enhanced green fluorescent protein (EGFP)-tagged HuIFN-beta revealed no difference in the subcellular distribution in either of the chimeric protein-expressing cells examined. These results suggest that the secretion polarity of HuIFN-beta is regulated by a post trans-Golgi network in a cell type-dependent manner.

    Web of Science

    researchmap

  • Simultaneous detection of DsRed2-tagged and EGFP-tagged human beta-interferons in the same single cells Reviewed

    M Maruyama, T Nishio, T Yoshida, C Ishida, K Ishida, Y Watanabe, M Nishikawa, Y Takakura

    JOURNAL OF CELLULAR BIOCHEMISTRY   93 ( 3 )   497 - 502   2004.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-LISS  

    The red fluorescent protein DsRed2 is a useful fusion tag for various proteins, together with the enhanced green fluorescent protein (EGFP). These chromoproteins have spectral properties that allow simultaneous distinctive detection of tagged proteins in the same single cells by dual color imaging. We used them for tagging a secretory protein, human interferon-beta (IFN-beta). Expression plasmids for human IFN-beta tagged with DsRed2 or with EGFP at the carboxyl terminal were constructed and their coexpression was examined in Mardin-Darby canine kidney epithelial cells. Although maturation of DsRed2 for coloration was slow and the color intensity was weak compared with EGFP, low temperature treatment (20degreesC) allowed DsRed2-tagged human IFN-beta to be detected in the cells using color imaging. Consequently, the two chimeric proteins were shown to be colocalized in the same single cells by dual color confocai microscopy. This approach will be useful for investigating subcellular localization of not only cell resident proteins but also secretory proteins.

    DOI: 10.1002/jcb.20203

    Web of Science

    researchmap

  • Subcellular trafficking of exogenously expressed interferon-beta in Madin-Darby canine kidney cells Reviewed

    M Maruyama, T Nishio, T Kato, T Yoshida, C Ishida, Y Watanabe, M Nishikawa, Y Kaneda, Y Takakura

    JOURNAL OF CELLULAR PHYSIOLOGY   201 ( 1 )   117 - 125   2004.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-LISS  

    We have recently demonstrated that when IFN-beta was exogenously expressed in epithelial cells, transiently expressed IFN-beta was predominantly secreted from the cell side to which the transfection was performed, while stably expressed one was almost equally secreted to the apical and basolateral sides. In the present study, we analyzed the subcellular transport of IFN-beta using confocal imaging with green fluorescent protein (GFP)-tagged IFN-beta in Madin-Darby canine kidney (MDCK) cells. Stably expressed and transiently expressed human IFN-beta (HuIFN-beta)-GFPs were seen in upper regions of the nucleus. In stable HuIFN beta-GFP-producing transformants, transiently expressed mouse IFN-beta (MuIFN-beta) was apparently co-localized with the bulk of the constitutive HuIFN beta-GFP proteins at TGN, and a significant quantity of them then appeared to pass into distinct post-TGN vesicles, accepting either type of IFN. Meanwhile, when cells were co-transfected with both expression vectors, transiently expressed both IFNs tended to co-localize not only at TGN but in post-TGN vesicles. These results suggest that stably and transiently expressed IFN-betas, albeit co-localized at TGN, were transported through apparently discriminated post-TGN routes.

    DOI: 10.1002/jcp.20038

    Web of Science

    researchmap

  • Expression and visualization of a human interferon-beta-enhanced green fluorescent protein chimeric molecule in cultured cells Reviewed

    M Nakamura, M Maruyama, F Yamashita, Y Takakura, M Hashida, Y Watanabe

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   27 ( 3 )   411 - 414   2004.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PHARMACEUTICAL SOC JAPAN  

    We have constructed a recombinant cDNA encoding the chimeric protein between human IFN-beta (HuIFN-beta) and enhanced green fluorescent protein (EGFP) to elucidate the intracellular localization of IFN-beta. Transient expression of the chimeric molecule, HuIFN-beta-EGFP, in L cells demonstrated that the chimeric molecule secreted from the cells had an intact biological activity as far as antiviral effect was concerned. Immunostaining of the transfected cells using anti-HuIFN-beta antibody demonstrated that green-fluorescence was co-localized with the IFN signal and its profile was similar to IFN signals in the cells transfected with HuIFN-beta expressing plasmid DNA. These results indicate that the HuIFN-beta-EGFP chimeric gene was expressed as a chimeric protein and the chimera was transported via the regular secretory pathway in the cells. In other cell types, the fluorescence derived from the chimeric protein was also seen on cytoplasmic vesicular structures. These results suggest that HuIFN-beta-EGFP will be a useful tool to investigate the intracellular trafficking processes of HuIFN-beta in a variety of cell types.

    Web of Science

    researchmap

  • Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I : poly C in a murine lung metastasis model Reviewed

    F Sakurai, T Terada, M Maruyama, Y Watanabe, F Yamashita, Y Takakura, M Hashida

    CANCER GENE THERAPY   10 ( 9 )   661 - 668   2003.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    We have evaluated and compared the efficacy of systemic administration of lipoplex formulations containing plasmids encoding IFN-beta or IFN-gamma, and a synthetic double-strand RNA poly I: poly C (pI: pC), a type I IFN inducer, in a lung metastasis model in which colon carcinoma CT-26 cells were inoculated intravenously into immunocompatible mice. Injection of lipoplexes containing plasmid DNA, regardless of IFN gene insertion, stimulated a transient increase in the serum concentration of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and IFN-gamma, while injection of lipoplexes containing pI: pC led to a low level of TNF-alpha and undetectable IFN-gamma production. Furthermore, injection of these lipoplexes containing plasmids resulted in the production of a mixture of type I and type II IFNs, partly derived from the inserted IFN genes, in lung tissue cultures. In tumor-prophylactic experiments, intravenous injection of lipoplexes containing plasmid, regardless of IFN gene insertion, showed a significant reduction in lung metastatic nodules probably due to proinflammatory cytokines such as TNF-alpha and IFN-gamma nonspecifically induced by the CpG motifs in the plasmid and the type I IFNs produced. On the other hand, the antimetastatic effect of pI: pC-lipoplex seemed to be due mainly to IFN-beta induced by pI: pC. In established lung metastasis experiments, a single intravenous administration of lipoplexes containing IFN-beta gene or pI: pC, but not other lipoplexes, showed a significant therapeutic effect on the tumor metastasis: reduction in tumor nodules and prolongation of survival time of tumor-burden mice. The therapeutic effects were specifically impaired by anti-IFN-beta antibody treatment, indicating that IFN-beta produced by the lipoplexes played an important role in the suppression of established metastatic lung tumors. Thus, the local IFN-beta in the lung delivered by intravenous administration of lipoplex containing IFN-beta gene or pI: pC may be a convenient and useful method of inhibiting established metastatic lung tumors.

    DOI: 10.1038/sj.cgt.7700617

    Web of Science

    researchmap

  • Secretion polarity of interferon-beta in epithelial cell lines Reviewed

    K Nakanishi, Y Watanabe, M Maruyama, F Yamashita, Y Takakura, M Hashida

    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS   402 ( 2 )   201 - 207   2002.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Epithelial cells are an attractive target for local gene delivery in gene therapy for which cytokine genes such as interferon (IFN) genes are promising. However, how the secretion of the gene products is regulated in epithelial cells has been insufficiently investigated. Here, we have studied the secretion polarity of IFN-beta expressed via gene transfection in mouse epithelial Pam-T cells on a bicameral culture system. In transient expression, IFN-beta was predominantly secreted from the cell membrane side on which the transfection was carried out. Meanwhile, the secretion of constitutive IFN-beta from stable transformants was apparently unpolarized. Interestingly, the transformants displayed a polarized secretion of transiently expressed IFN-beta in a transfection-side-dependent manner, their stable IFN-beta secretion remaining unpolarized. These results suggest that epithelial cells have at least dual protein sorting-secretion pathways, transient and stable, for the same secretory proteins, such as IFNs. (C) 2002 Elsevier Science (USA). All rights reserved.

    Web of Science

    researchmap

  • Modulation of intestinal permeability by nitric oxide donors: Implications in intestinal delivery of poorly absorbable drugs Reviewed

    A Yamamoto, H Tatsumi, M Maruyama, T Uchiyama, N Okada, T Fujita

    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS   296 ( 1 )   84 - 90   2001.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS  

    The effects of nitric oxide (NO) donors NOC5 [3-(2-hydroxy-1-(methylethyl)- 2-nitrosohydrazino)-1-propanamine] and NOC12 [N-ethyl-2-(1-ethyl-hydroxy-2-nitrosohydrazino)-ethanamine] on the permeability of 5(6)-carboxyfluorescein (CF) across the intestinal membrane were examined by an in vitro Ussing chamber method. The NO donors significantly increased the intestinal permeability of CF and their absorption-enhancing effects were concentration-dependent over the range of 0.01 to 0.1 mM. Regional differences in the absorption-enhancing effects of the NO donors were observed (colon. jejunum). The absorption-enhancing effect of NOC12 reduced as the molecular weights of compounds increased. Therefore, the degree of absorption-enhancing effect of NOC12 was dependent on the molecular weights of compounds. In the pretreatment studies with NOC12 and lactate dehydrogenase release studies, the absorption-enhancing effect of 0.1 mM NOC12 was reversible and less toxic to the colonic membrane. On the other hand, the absorption-enhancing effect of NOC12 was inhibited by the coadministration of 2-(4-carboxyphenyl) 4,4,5,5-tetramethylimidazole- 1-oxyl 3-oxide sodium salt, an NO scavenger, suggesting that NO can regulate the permeability of water-soluble drugs in the gut. Furthermore, NOC12 (0.1 and 1 mM) significantly decreased the transepithelial electrical resistance value of the colonic membrane, suggesting that the absorption-enhancing mechanism of NOC12 may be partly related to the dilation of the tight junction in the epithelium via a paracellular route. These findings suggest that NO donors may be useful to enhance the intestinal absorption of poorly absorbable drugs.

    Web of Science

    researchmap

▼display all

Books

  • Aminopeptidase Q/Laveverin「Handbook of Proteolytic Enzymes」

    Hattori A, Maruyama M, Fujiwara H, Tsujimoto M( Role: Joint author)

    Academic Press  2013  ( ISBN:9780123822192

     More details

    Responsible for pages:442-444   Book type:Scholarly book

    researchmap

MISC

  • イオン輸送体を分子標的としたがん幹細胞の新規治療法の開発

    林 美樹夫, 海堀 昌樹, 松田 達志, 丸山 正人, 岩田 亮一, 齊藤 朋人, 中野 洋輔

    関西医科大学雑誌   69   46 - 46   2018.12

     More details

    Language:Japanese   Publisher:関西医科大学医学会  

    researchmap

  • ヒト神経膠芽腫由来U87MG細胞から樹立した高い腫瘍形成能を持つスフェロイドはPC3-Secreted Microproteinを高発現する

    丸山 正人, 中野 洋輔, 岩田 亮一, 西村 拓也, 加瀬 政彦, 杉本 哲夫

    生命科学系学会合同年次大会   2017年度   [3P - 0964]   2017.12

     More details

    Language:Japanese   Publisher:生命科学系学会合同年次大会運営事務局  

    researchmap

  • DiI注入法によるBcas1 in situ hybridization陽性細胞の形態描出

    加瀬 政彦, 山下 雄司, Trifonov Stefan, 丸山 正人, 杉本 哲夫

    日本組織細胞化学会総会・学術集会講演プログラム・予稿集   56回   82 - 82   2015.10

     More details

    Language:Japanese   Publisher:日本組織細胞化学会  

    researchmap

  • 神経幹細胞特異的に発現させた薬剤耐性遺伝子によるマウスiPS細胞由来神経幹細胞の純化

    丸山 正人, 山下 雄司, Trifonov Stefan, 加瀬 政彦, 杉本 哲夫

    日本薬学会年会要旨集   133年会 ( 3 )   206 - 206   2013.3

     More details

    Language:Japanese   Publisher:(公社)日本薬学会  

    researchmap

  • マウス線条体のV字型縞構造

    山下 雄司, ステファン・トリフォノフ, 宝谷 剛志, 丸山 正人, 加瀬 政彦, 杉本 哲夫

    解剖学雑誌   87 ( 2 )   38 - 38   2012.6

     More details

    Language:Japanese   Publisher:(一社)日本解剖学会  

    researchmap

  • 薬剤選択によるマウスiPS細胞由来神経幹細胞の純化

    丸山 正人, 山下 雄司, トリフォノフ・ステファン, 加瀬 政彦, 杉本 哲夫

    日本生化学会大会プログラム・講演要旨集   84回   3P - 0400   2011.9

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

    researchmap

  • Reconstruction of calbindin-poor lateral striatum in the mouse

    Yuji Yamashita, Stefan Trifonov, Takeshi Houtani, Masato Maruyama, Masahiko Kase, Jun-ichi Shimizu, Tetsuo Sugimoto

    NEUROSCIENCE RESEARCH   71   E140 - E140   2011

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2011.07.605

    Web of Science

    researchmap

  • Purification of neural stem cells derived from mouse induced pluripotent stem cells by drug selection

    Masato Maruyama, Yuji Yamashita, Stefan Trifonov, Masahiko Kase, Jun-ichi Shimizu, Tetsuo Sugimoto

    NEUROSCIENCE RESEARCH   71   E330 - E330   2011

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2011.07.1443

    Web of Science

    researchmap

  • GPR155-遺伝子の構成とマウス脳内mRNA発現の解析(GPR155: gene organization and expression in mouse brain)

    Trifonov Stefan, 宝谷 剛志, 清水 順一, 山下 雄司, 濱田 聡子, 加瀬 政彦, 丸山 正人, 杉本 哲夫

    神経化学   49 ( 2-3 )   548 - 548   2010.8

     More details

    Language:English   Publisher:日本神経化学会  

    researchmap

  • ラット中枢神経系におけるPMES-2遺伝子発現細胞の特徴的な分布

    加瀬 政彦, 宝谷 剛志, 丸山 正人, トリフォノフ・ステファン, 清水 順一, 杉本 哲夫

    解剖学雑誌   85 ( Suppl. )   189 - 189   2010.3

     More details

    Language:Japanese   Publisher:(一社)日本解剖学会  

    researchmap

  • GPR155-gene organization and expression in mouse brain

    Stefan Trifonov, Takeshi Houtani, Jun-ichi Shimizu, Yuji Yamashita, Satoko Hamada, Masahiko Kase, Masato Maruyama, Tetsuo Sugimoto

    NEUROSCIENCE RESEARCH   68   E147 - E147   2010

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2010.07.2224

    Web of Science

    researchmap

  • 薬剤選択を利用したマウス人工多能性幹細胞由来神経幹細胞の効率的純化

    丸山 正人, 室谷 剛志, Trifonov Stefan, 加瀬 政彦, 杉本 哲夫

    日本生化学会大会プログラム・講演要旨集   82回   2P - 760   2009.9

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

    researchmap

  • Choline acetyltransferase mRNA splice variants マウス脳・脊髄での発現

    トリフォノフ・ステファン, 宝谷 剛志, 濱田 聡子, 加瀬 政彦, 丸山 正人, 杉本 哲夫

    解剖学雑誌   84 ( Suppl. )   249 - 249   2009.3

     More details

    Language:English   Publisher:(一社)日本解剖学会  

    researchmap

  • Effective purification of neural stem cells derived from mouse induced pluripotent stem cells

    Masato Maruyama, Takeshi Houtani, Stefan Trifonov, Masahiko Kase, Tetsuo Sugimoto

    NEUROSCIENCE RESEARCH   65   S93 - S93   2009

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2009.09.389

    Web of Science

    researchmap

  • Distinct regional differences in the expression pattern of the transcripts of the cholinergic gene locus

    Stefan Trifonov, Takeshi Houtani, Satoko Hamada, Masahiko Kase, Masato Maruyama, Jun-ichi Shimizu, Tetsuo Sugimoto

    NEUROSCIENCE RESEARCH   65   S75 - S75   2009

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2009.09.267

    Web of Science

    researchmap

  • M1アミノペプチダーゼファミリーの生理的/病理学的機能

    服部明, 服部明, 丸山正人, 後藤芳邦, 辻本雅文

    ケミカルバイオロジーシンポジウム発表要旨集 第4回 化学-生物融合領域創成の軌跡 理研シンポジウム 平成20年   2008

  • インターフェロン・GFP融合タンパクの極性上皮細胞内輸送過程の解析

    丸山 正人, 石田 智早希, 渡部 好彦, 高倉 喜信

    薬剤学 = Journal of Pharmaceutical Science and Technology, Japan   63   125 - 125   2003.3

     More details

  • 腎上皮細胞LLC-PK_1におけるインターフェロンの細胞内動態と分泌方向性の解析

    吉田 豊一, 西尾 照子, 丸山 正人, 渡部 好彦, 高倉 喜信

    薬剤学 = Journal of Pharmaceutical Science and Technology, Japan   63   126 - 126   2003.3

     More details

▼display all

Presentations

  • Paracellular routeを介した薬物透過性に及ぼす腸神経系の影響に関する基礎的研究

    吉形 南美, 坂口 真菜, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会年会講演要旨集  2020.5  (公社)日本薬剤学会

     More details

    Event date: 2020.5

    Language:Japanese  

    researchmap

  • ポリアミン誘導体を用いた薬物吸収改善の機構に関する基礎的研究

    渡邊 菜摘, 小林 紘子, 三宅 正晃, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会年会講演要旨集  2020.5  (公社)日本薬剤学会

     More details

    Event date: 2020.5

    Language:Japanese  

    researchmap

  • Self-nanoemulsifying Drug Delivery Systemによる難水溶性薬物Clofazimineの経口吸収挙動改善とその機構解析に関する研究

    山之内 慶太, 石丸 智基, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会年会講演要旨集  2020.5  (公社)日本薬剤学会

     More details

    Event date: 2020.5

    Language:Japanese  

    researchmap

  • パクリタキセル内封リポソーム製剤の転移性乳がんモデルマウスにおける抗腫瘍効果に及ぼす血管正常化の影響

    松井 はづき, 高杉 裕太, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会年会講演要旨集  2020.5  (公社)日本薬剤学会

     More details

    Event date: 2020.5

    Language:Japanese  

    researchmap

  • ドキソルビシン内封リポソーム製剤の悪性黒色腫固形がん治療に及ぼす薬物放出特性の影響

    家中 悠輔, 東條 遥佳, 兵頭 健治, 石原 比呂之, 菊池 寛, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会年会講演要旨集  2020.5  (公社)日本薬剤学会

     More details

    Event date: 2020.5

    Language:Japanese  

    researchmap

  • 難溶解性薬物イブプロフェン及びラロキシフェンの経口吸収挙動の解析と予測

    近藤敬二, 河津翔, 妹尾遼太郎, 大河原賢一, 丸山正人, 檜垣和孝

    日本薬物動態学会第34回年会 

     More details

    Event date: 2019.12.9 - 2019.12.12

    Presentation type:Oral presentation (general)  

    researchmap

  • 血管新生阻害剤SU-5416による血管正常化療法ががん関連繊維芽細胞に及ぼす影響

    中村 遥, 松井 はづき, 高杉 裕太, 大河原 賢一, 丸山 正人, 檜垣 和孝

    第38回日本DDS学会学術集会  2022.6.29 

     More details

  • マウス乳がん由来4T1細胞におけるがん幹細胞様のモデル細胞株樹立に関する研究

    瀬口 実穂, 丸山 正人, 檜垣 和孝

    第38回日本DDS学会学術集会  2022.6.29 

     More details

  • ドキソルビシン(DOX)耐性腫瘍に対するDOX-PEGリポソームの抗腫瘍効果に及ぼす腫瘍組織内血管内皮細胞特性の影響

    上田 智樹, 家中 悠輔, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会第37年会  2022.5.27 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • 血管新生阻害剤 SU5416 - パクリタキセル (PTX) 内封 PEG リポソームの 逐次的頻回併用療法の転移性乳がん4T1担がんマウスにおける抗腫瘍効果

    鳥井 怜冶, 松井 はづき, 高杉 裕太, 大河原 賢一, 丸山 正人, 檜垣 和孝

    日本薬剤学会第37年会  2022.5.27 

     More details

  • 難水溶性薬物ClofazimineのSelf-nanoemulsifying Drug Delivery System(SNEDDS)による経口吸収挙動改善機構の解析

    林 佳佑, 山之内 慶太, 石丸 智基, 丸山 正人, 檜垣 和孝

    日本薬剤学会第37年会  2022.5.26 

     More details

  • 初代培養腸神経系細胞―Caco-2 細胞共培養系を用いた腸神経系による腸上皮細胞透過性制御に関する基礎的研究: 受動拡散による薬物透過に関する検討

    枠島 静, 吉形 南美, 丸山 正人, 檜垣 和孝

    日本薬剤学会第37年会  2022.5.26 

     More details

  • 難水溶性-難脂溶性薬物メベンダゾールのカウンターイオンを用いたSNEDDS (Self-nanoemulsifying Drug Delivery System)製剤化と吸収挙動改善に関する研究

    井上 知也, 住元 祐介, 大川 慎也, 丸山 正人, 檜垣 和孝

    日本薬剤学会第36年会  2021.5.14 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • ポリアミン誘導体OPI-331を用いた新規吸収改善製剤開発のための基礎的研究

    武林 翔, 宮里 萌花, 渡邊 菜摘, 三宅 正晃, 大河原賢一, 丸山正人, 檜垣 和孝

    日本薬剤学会第36年会  2021.5.13 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • Self-nanoemulsifying Drug Delivery System による難水溶性薬物 Resveratrol の経口吸収改善とその機構解析に関する研究

    竹本 雄貴, 近藤 敬二, 丸山 正人, 檜垣 和孝

    日本薬剤学会第36年会  2021.5.13 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • ヒト神経膠芽腫由来U87MG細胞から樹立した高い腫瘍形成能を持つスフェロイドはPC3-Secreted Microproteinを高発現する

    丸山正人, 中野洋輔, 岩田亮一, 西村拓也, 加瀬政彦, 杉本哲夫

    2017年度生命科学系学会合同年次大会(ConBio2017)第40回日本分子生物学会年会 第90回日本生化学会大会  2017.12.8 

     More details

    Venue:神戸  

    researchmap

  • 神経内分泌腫瘍の転移脳組織からの癌幹細胞

    岩田亮一, 丸山正人, 伊藤量基, 中野洋輔, 小池太郎, 大江聡一, 吉村晋一, 埜中正博, 野村昌作, 杉本哲夫, 山田久夫, 淺井昭雄

    第49回日本臨床分子形態学会総会・学術集会  2017.9 

     More details

    Venue:岐阜  

    researchmap

  • 転移性脳腫瘍からのがん幹細胞株樹立

    岩田亮一, 丸山正人, 中野洋輔, 小池太郎, 大江聡一, 吉村晋一, 埜中正博, 杉本哲夫, 山田久夫, 淺井昭雄

    第27回日本サイトメトリー学会学術集会  2017.6 

     More details

    Venue:神戸  

    researchmap

  • 成熟ラット脳におけるBcas1 mRNA発現細胞の免疫組織化学的および形態学的解析

    加瀬政彦, 山下雄司, 中野洋輔, 丸山正人, 杉本哲夫

    第122回日本解剖学会総会・全国学術集会  2017.3 

     More details

    Venue:長崎  

    researchmap

  • マウス線条体のGPR155陽性interneuron

    山下雄司, Trifonov Stefan, 丸山正人, 加瀬政彦, 中野洋輔, 杉本哲夫

    第122回日本解剖学会総会・全国学術集会  2017.3 

     More details

    Venue:長崎  

    researchmap

  • マウス脳GPR155の機能解明へのアプローチ

    山下雄司, Trifonov Stefan, 加瀬政彦, 丸山正人, 中野洋輔, 西村拓也, 杉本哲夫

    第39回日本神経科学大会  2016.7 

     More details

    Venue:横浜  

    researchmap

  • マウス線条体外側部のD1ニューロンはGPR155を発現している

    山下雄司, Trifonov Stefan, 丸山正人, 加瀬政彦, 杉本哲夫

    第121回日本解剖学会総会・全国学術集会  2016.3 

     More details

    Venue:郡山  

    researchmap

  • DiI注入法によるBcas1 in situ hybridization陽性細胞の形態抽出

    加瀬政彦, 山下雄司, Trifonov Stefan, 丸山正人, 杉本哲夫

    第56回日本組織細胞化学会総会・学術集会  2015.10 

     More details

    Venue:枚方  

    researchmap

  • In situ hybridization標識細胞の総合的解析法

    加瀬政彦, 山下雄司, Trifonov Stefan, 丸山正人, 杉本哲夫

    第120回日本解剖学会総会・全国学術集会 第92回日本生理学会大会 合同大会  2015.3 

     More details

    Venue:神戸  

    researchmap

  • 線条体外側部の機能構築

    山下雄司, Trifonov Stefan, 丸山正人, 加瀬政彦, 杉本哲夫

    高次機能代謝系・ブレインメディカルサイエンス系大学院生研究中間発表会  2014.7 

     More details

    Venue:枚方  

    researchmap

  • 機械的障害後の成熟ラット脳におけるBcas1遺伝子発現細胞の分布変化

    加瀬政彦, 丸山正人, トリフォノフ ステファン, 山下雄司, 杉本哲夫

    第119回日本解剖学会総会・全国学術集会  2014.3 

     More details

    Venue:下野  

    researchmap

  • マウスGPR155陽性線条体ニューロンの共存物質

    山下雄司, 丸山正人, トリフォノフ ステファン, 加瀬政彦, 杉本哲夫

    日本解剖学会第89回近畿支部学術集会  2013.11 

     More details

    Venue:生駒  

    researchmap

  • GPR抗体を用いたマウス線条体外側部V字型縞構造の解析

    山下雄司, Trifonov Stefan, 丸山正人, 加瀬政彦, 杉本哲夫

    第118回日本解剖学会総会・全国学術集会  2013.3 

     More details

    Venue:高松  

    researchmap

  • 神経幹細胞特異的に発現させた薬剤耐性遺伝子によるマウスiPS細胞由来神経幹細胞の純化

    丸山正人, 山下雄司, Trifonov Stefan, 加瀬政彦, 杉本哲夫

    日本薬学会第133年会  2013.3 

     More details

    Venue:横浜  

    researchmap

  • 成獣ラット脳の機械的外傷後にみられる傷周辺組織でのPMES-2遺伝子発現細胞の増加

    加瀬政彦, 丸山正人, Trifonov Stefan, 山下雄司, 杉本哲夫

    第117回日本解剖学会総会・全国学術集会  2012.3 

     More details

    Venue:甲府  

    researchmap

  • マウス線条体外側部マーカー物質のV字型縞構造への局在

    山下雄司, Trifonov Stefan, 宝谷剛志, 丸山正人, 加瀬政彦, 杉本哲夫

    第117回日本解剖学会総会・全国学術集会  2012.3 

     More details

    Venue:甲府  

    researchmap

  • マウス線条体のV字型縞構造

    山下雄司, ステファン トリフォノフ, 宝谷剛志, 丸山正人, 加瀬政彦, 杉本哲夫

    第87回日本解剖学会近畿支部学術集会  2011.12 

     More details

    Venue:西宮  

    researchmap

  • マウス線条体の区分

    山下雄司, 丸山正人, 加瀬政彦, Trifonov Stefan, 清水順一, 杉本哲夫

    第9回近畿大学環境科学研究会  2010.8 

     More details

    Venue:東大阪  

    researchmap

  • ラット中枢神経系におけるPMES-2遺伝子発現細胞の特徴的な分布

    Kase M, Houtani T, Maruyama M, Trifonov S, Shimizu J, Sugimoto T

    第115回日本解剖学会総会・全国学術集会  2010.3 

     More details

    Venue:盛岡  

    researchmap

  • 薬剤選択を利用したマウス人工多能性幹細胞由来神経幹細胞の効率的純化

    Maruyama M, Houtani T, Trifonov S, Kase M, Sugimoto T

    第82回日本生化学大会  2009.10 

     More details

    Venue:神戸  

    researchmap

  • マウスiPS細胞から分化させた神経幹細胞の効率的純化

    Maruyama M, Houtani T, Trifonov S, Kase M, SugimotoT

    第32回日本神経科学大会  2009.9 

     More details

    Venue:名古屋  

    researchmap

  • Choline acetyltransferase mRNA splice variants -マウス脳・脊髄での発現

    Trifonov S, Houtani T, Hamada S, Kase M, Maruyama M, Sugimoto T

    第114回日本解剖学会総会・全国学術集会  2009.3 

     More details

    Venue:岡山  

    researchmap

  • 点変異導入によるヒトLaeverinのHis379残基の機能解析

    有坂尚美, 丸山正人, 服部明, 辻本雅文

    第31回日本分子生物学会年会・第81回日本生化学会大会合同大会  2008.12 

     More details

    Venue:神戸  

    researchmap

  • Expression of ChAT mRNA splice variants in mouse CNS

    Stefan Trifonov, 宝谷剛志, 濱田聡子, 加瀬政彦, 丸山正人, 杉本哲夫

    第84回日本解剖学学会近畿支部学術集会  2008.11 

     More details

    Venue:大阪  

    researchmap

  • ヒトLaeverinの酵素学的性状の発現におけるHis379残基の役割

    有坂尚美, 丸山正人, 服部明, 辻本雅文

    病態と治療におけるプロテアーゼとインヒビター学会  2008.8 

     More details

    Venue:大阪  

    researchmap

  • 中枢聴覚路におけるコリン線維とムスカリン性受容体サブタイプ発現の解析

    濱田聡子, 宝谷剛志, Stefan Trifonov, 丸山正人, 加瀬政彦, 堤俊之, 杉本哲夫, 友田幸一, 山下敏夫

    第26回頭頚部自律神経研究会  2008.8 

     More details

    Venue:大阪  

    researchmap

  • ヒトLaeverin/Aminopeptidase QのHis379残基の機能解析

    丸山正人, 有坂尚美, 服部 明, 辻本雅文

    日本薬学会第128年会  2008.3 

     More details

    Venue:横浜、日本  

    researchmap

  • 新規M1アミノペプチダーゼLaeverinの酵素学的性状の解析

    丸山正人, 服部明, 辻本雅文

    第4回ケミカルバイオロジーシンポジウム  2008.2 

     More details

    Presentation type:Symposium, workshop panel (nominated)  

    Venue:静岡、日本  

    researchmap

  • 新規ロイシンアミノペプチダーゼLaeverinの機能解析

    服部 明, 丸山 正人, 辻本雅文

    第30回日本分子生物学会年会第80回日本生化学会大会合同大会  2007.12 

     More details

    Presentation type:Symposium, workshop panel (nominated)  

    Venue:横浜、日本  

    researchmap

  • 新規アミノペプチダーゼLaeverinの酵素学的性状の解析

    丸山 正人, 服部 明, 辻本 雅文

    第30回日本分子生物学会年会第80回日本生化学会大会合同大会  2007.12 

     More details

    Venue:横浜、日本  

    researchmap

  • Laeverin: a novel bestatin sensitive leucine aminopeptidase belonging to the M1 family of aminopeptidases International conference

    Masato Maruyama, Akira Hattori, Masafumi Tsujimoto

    5th General Meeting of the International Proteolysis Society  2007.10 

     More details

    Venue:Patras, Greece  

    researchmap

  • 新規酵素Laeverinの酵素学的性状解析

    丸山正人, 服部 明, 辻本雅文

    第12回病態と治療におけるプロテアーゼとインヒビター学会  2007.8 

     More details

    Venue:大阪、日本  

    researchmap

  • Substance P stimulates the cell surface translocation of angiotensin IV receptor/placental leucine aminopeptidase in PC12 cells

    Masato Maruyama, Akira Hattori, Masafumi Tsujimoto

    RIKEN International Symposium on Chemical Biology  2007.1 

     More details

    Venue:Kanagawa, Japan  

    researchmap

  • サブスタンスPは神経細胞においてアンギオテンシンIV受容体/胎盤性ロイシンアミノペプチダーゼの細胞膜移行を誘導する

    丸山正人, 服部 明, 辻本雅文

    第28回生体膜と薬物の相互作用シンポジウム  2006.11 

     More details

    Presentation type:Symposium, workshop panel (nominated)  

    Venue:静岡、日本  

    researchmap

  • サブスタンスPによる胎盤性ロイシンアミノペプチダーゼの細胞膜移行誘導

    丸山正人, 服部 明, 辻本雅文

    第11回病態と治療におけるプロテアーゼとインヒビター研究会  2006.8 

     More details

    Venue:仙台、日本  

    researchmap

  • 上皮細胞に発現させたインターフェロンの分泌方向性制御の試み

    石田香代, 吉田豊一, 丸山正人, 渡部好彦, 西川元也, 高倉喜信

    日本薬学会第125年会  2005.3 

     More details

    Venue:東京、日本  

    researchmap

  • 極性上皮細胞へのインターフェロン遺伝子導入後の分泌方向性に関する研究

    丸山正人

    創剤フォーラム第10回若手研究会  2004.11 

     More details

    Venue:京都、日本  

    researchmap

  • Mechanism of Polarized Secretion Erythropoietin in Mardin-Darby Canine Kidney Cells International conference

    Kayo Ishida, Masato Maruyama, Yoshihiko Watanabe, Yoshinobu Takakura

    5th Globalization of Pharmaceutics Education Network  2004.5 

     More details

    Venue:Kyoto, Japan  

    researchmap

  • Effects of cholesterol depletion on secretion polarity of human interferon-  in Mardin-Darby canine kidney cells International conference

    Kayo Ishida, Masato Maruyama, Yoshihiko Watanabe, Yoshinobu Takakura

    2nd World Congress of the Board of Pharaceutical Sciences of FIP  2004.5 

     More details

    Venue:Kyoto, Japan  

    researchmap

  • 上皮細胞におけるインターフェロンの細胞内輸送動態の解析:分泌方向性制御を目指して

    丸山正人, 石田智早希, 渡部好彦, 高倉喜信

    日本DDS学会第19年会  2003.6 

     More details

    Venue:京都、日本  

    researchmap

  • インターフェロン・GFP融合タンパクの極性上皮細胞内輸送過程の解析

    丸山正人, 石田智早希, 渡部好彦, 高倉喜信

    日本薬剤学会第18年会  2003.4 

     More details

    Venue:京都、日本  

    researchmap

  • 腎上皮細胞 LLC-PK1におけるインターフェロンの細胞内動態と分泌方向性の解析

    吉田豊一, 西尾照子, 丸山正人, 渡部好彦, 高倉喜信

    日本薬剤学会第18年会  2003.4 

     More details

    Venue:京都、日本  

    researchmap

  • 細胞内動態解析ツールとしてのインターフェロン・DsRed 融合タンパク発現ベクターの構築

    丸山正人, 西尾照子, 石田智早希, 渡部好彦, 高倉喜信

    日本薬学会第123年会  2003.3 

     More details

    Venue:長崎、日本  

    researchmap

  • Analysis of secretion polarity after gene delivery to epithelial cells International conference

    Masato Maruyama, Yoshihiko Watanabe, Yoshinobu Takakura

    4th Globalization of Pharmaceutics Education Network  2002.11 

     More details

    Venue:Michigan, USA  

    researchmap

  • 腎上皮細胞LLC-PK 1におけるインターフェロン・GFP融合タンパクの細胞内動態と分泌方向性の解析

    西尾照子, 丸山正人, 渡部好彦, 高倉喜信

    日本薬物動態学会第17年会  2002.11 

     More details

    Venue:千葉、日本  

    researchmap

  • Secretion polarity and intracellular transport of interferon-GFP fusion protein after gene delivery to epithelial cells International conference

    Masato Maruyama, Toyokazu Yoshida, Yoshihiko Watanabe, Yoshinobu Takakura

    29th Annual Meeting and Exposition of the Controlled Release Society  2002.7 

     More details

    Venue:Seoul, Korea  

    researchmap

  • 上皮細胞におけるインターフェロン・GFP 融合タンパクの細胞内輸送過程の解析

    丸山正人, 吉田豊一, 渡部好彦, 高倉喜信

    日本薬学会第122年会  2002.3 

     More details

    Venue:千葉、日本  

    researchmap

  • 上皮細胞をターゲットとしたインターフェロン遺伝子デリバリーとその分泌方向性: GFP 融合タンパクを用いた解析

    丸山正人, 加藤貴子, 渡部好彦, 高倉喜信

    日本薬学会第121年会  2001.3 

     More details

    Venue:札幌、日本  

    researchmap

  • 極性を有する上皮細胞へのインターフェロン遺伝子のデリバリーとそのエキソサイトーシス方向性

    丸山正人, 中西貴代, 渡部好彦, 橋田 充, 高倉喜信

    第22回生体膜と薬物の相互作用シンポジウム  2000.11 

     More details

    Presentation type:Symposium, workshop panel (nominated)  

    Venue:京都、日本  

    researchmap

  • Polarized secretion of IFN-beta in epithelial cells following gene transfer with IFN-beta encoding plasmid International conference

    Masato Maruyama, Kiyo Nakanishi, Yoshihiko Watanabe, Mitsuru Hashida, Yoshinobu Takakura

    Millennial World Congress of Pharmaceutical Sciences  2000.4 

     More details

    Venue:San Francisco, USA  

    researchmap

▼display all

Awards

  • ポスター奨励賞

    2006.8   病態と治療におけるプロテアーゼとインヒビター研究会  

     More details

Research Projects

  • Effect of ENS dysfunction on drug absorption from small intestine

    Grant number:20K07176  2020.04 - 2025.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    檜垣 和孝, 丸山 正人, 大河原 賢一

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    申請者らは、これまでに5-HT代謝異常ラットにおいて、i) Cephalexin (CEX) の経口投与後の吸収が増大すること, ii)CEXの吸収の一翼を担うPEPT1の小腸における発現は、粘膜ホモジネート中では変化が認められなかったが、小腸上皮細胞刷子縁膜上のPEPT1は有意に減少しており、PEPT1を介した膜透過はむしろ低下していること、iii)細胞間隙経路を介した受動拡散による膜透過が増大し、特に回腸において有意な増大となっていること、等を明らかにしてきた。本年度は、5-HT代謝異常ラットにおけるgastrointestinal transitの変動の可能性を検討し、前年までに明らかにした膜透過性変動との関係から、経口投与後の吸収性変動について考察を試みた。難水溶性色素phenol redをマーカーとして胃排出挙動を、また微小なガラスビーズをマーカーとして小腸内移行性を評価したところ、胃、十二指腸、空腸上部では、それぞれの消化管部位における移行性が亢進傾向にあること、一方で、空腸下部、回腸上部、回腸下部では、逆に移行性の低下、即ち滞留性が増大傾向にあることが明らかとなった。これは、CEXの透過亢進が起こっている回腸において滞留性が増大していることを意味しており、このことが経口投与後のCEX吸収増大を促したものと考えられた。また、CEXを5-HT代謝異常ラットに静脈内投与し、吸収過程以外の過程におけるCEXの動態変動の可能性を検討した。その結果、分布や血漿中からの初期の消失には、変動は認められなかったが、血漿中からの消失相における消失が、有意に遅延していることが明らかとなった。CEXは、腎臓の近位尿細管に存在しているPEPT2により再吸収されていることが知られていることから、腎の刷子縁膜上に発現しているPEPT2をWestern blot法により定量的に評価した。その結果、有意な減少が認められたことから、PEPT2を介した再吸収の低下が、血漿中からの消失の遅延の要因の一つと考えられた。

    researchmap

  • Establishment of a novel drug delivery system for targeting cancer stem cells based on the structual analysis of tumor blood vesseles.

    Grant number:20K07155  2020.04 - 2023.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    丸山 正人, 檜垣 和孝

      More details

    Grant amount:\4290000 ( Direct expense: \3300000 、 Indirect expense:\990000 )

    本研究では、腫瘍血管の構造解析に基づいたがん幹細胞への新規薬物送達法を確立し、がん幹細胞を標的とした新規治療法の開発を目指している。昨年度は、マウス4T1乳がん細胞を用いて、乳がん幹細胞の候補となり得るクローン株を複数(4種類)樹立した。そこで、本年度は、樹立したこれらのクローン株が、がん幹細胞の特性を有することを明らかにすることを目的に、腫瘍形成能とがん幹細胞マーカーの発現について、検討を行った。
    樹立した細胞を、5週齢のBalb/cマウスの皮下に1x106個の細胞を移植し、腫瘍形成能を評価したところ、移植した4種類のクローン株のうち、2種類のクローン株において、親株に比べて有意に高い腫瘍形成能を示すことが確認された。さらに、細胞数を5x105個に少なくして投与した場合についても検討を行った結果、1x106個の細胞を移植したときに高い腫瘍形成能を示した2種類のクローン株が、5x105個の細胞を投与した時にも、親株に比べて有意に高い腫瘍形成能を示すことが確認されたため、これらのクローン株が、がん幹細胞の有用な候補と考えられた。
    次に、がん幹細胞マーカーの発現について検討を行った。樹立した細胞は、ALDH1A1 mRNAの発現量に基づいてスクリーニングされた細胞であるため、既知のがん幹細胞であるALDH1A1に着目し、そのタンパクレベルの発現を免疫染色法を用いて解析した。その結果、高い腫瘍形成能を示した2種類のクローン株において、ALDH1A1の高い発現を確認できた。
    以上のことから、本年度は、樹立したがん幹細胞のモデル細胞のうち、2種類の細胞がin vivoにおいて高い腫瘍形成能を示すこと、これらの細胞では、ALDH1A1ががん幹細胞マーカーとして発現することを明らかにした。今後、これらの細胞が、がん幹細胞への新規薬物送達法を確立するための有用なモデル細胞になると考えらえれた。

    researchmap

  • グリオーマ癌幹細胞特異的に発現する新規バイオマーカーの機能解析

    2017.04

    基盤研究(C)

      More details

    Grant type:Competitive

    researchmap

  • Funcional analysis of a novel biomarker specifically expressed in glioma stem cell.

    Grant number:17K07183  2017.04 - 2020.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Maruyama Masato

      More details

    Grant amount:\5070000 ( Direct expense: \3900000 、 Indirect expense:\1170000 )

    We analyzed the expression of PC3-secreted microseminoprotein (MSMP) in glioma stem cells and indicated that MSMP was expressed in patient-derived glioma stem cell lines and human glioma tissues. These results suggested that MSMP expressed in glioma stem cells migrate peripheral blood monocytes from blood vessele to tumor tissues and contributed to the formation of tumor microenvironment.

    researchmap

  • グリオーマ癌幹細胞特異的に発現する新規バイオマーカーの機能解析

    2017

    日本学術振興会  基盤研究(C)

    丸山 正人

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\780000 ( Direct expense: \780000 )

    researchmap

  • グリオーマ癌幹細胞特異的に発現する新規バイオマーカーの機能解析

    2017 - 2019

    日本学術振興会  基盤研究(C)

    丸山 正人

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3300000 ( Direct expense: \3300000 )

    researchmap

  • グリオーマ癌幹細胞特異的に発現する新規バイオマーカーの機能解析

    2017 - 2019

    日本学術振興会  基盤研究(C)

    丸山 正人

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\1820000 ( Direct expense: \1820000 )

    researchmap

  • グリオーマ癌幹細胞特異的に発現する新規バイオマーカーの機能解析

    2017 - 2019

    日本学術振興会  基盤研究(C)

    丸山 正人

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\2700000 ( Direct expense: \2700000 )

    researchmap

  • Novel therapeutic strategy for glioma by construction of glioma stem cell specific gene expression system.

    Grant number:25460049  2013.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    MARUYAMA Masato, KASE Masahiko, TRIFONOV Stefan, SAKURAI Fuminori

      More details

    Grant amount:\5070000 ( Direct expense: \3900000 、 Indirect expense:\1170000 )

    Gliomas are most common type of brain tumor and malignant gliomas have high recurrence rates and poor prognosis. In recent years, cancer stem cells are considered to be a cause of metastasis and recurrence after treatment. Since past therapeutic strategy against glioma targets whole tumor cells, these strategy are not effective for cancer stem cells which shows resistant to therapy. Here, we established human glioma stem cell lines and constructed molecular basis to specifically express therapeutic genes in glioma stem cells.

    researchmap

  • Biochemical and physiological studies on deubiquitinating enzymes based on an analysis of the enzymatic activity dynamics

    Grant number:23310160  2011.04 - 2014.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    HATTORI Akira, OISHI Shinya, FUJIWARA Hiroshi, INOUE Hideshi, MARUYAMA Masato, NISHIMURA Shinichi

      More details

    Grant amount:\20020000 ( Direct expense: \15400000 、 Indirect expense:\4620000 )

    Post-translational modification of cellular proteins by ubiquitin (Ub) is involved in various aspects of cell physiology, such as protein degradation via proteasome, DNA repair, and membrane trafficking. Deubiqutinating enzymes liberate a Ub moiety from polyUb chains attached on substrate proteins. In the current study, we investigated novel research tools for the enzymatic characterization of deubiquitinating enzymes. Ub-granzyme B (Ub-GrB), an N-terminal Ub fusion mature granzyme B was expressed in a baculovirus system. By employing Ub-GrB, we showed that human ubiquitin specific protease 47 is active. In addition, we explored oxidative stress-sensitive deubiquitinating enzymes, and found that ubiquitin C-terminal hydrolase-L3 is susceptible to reactive oxygen species by utilizing a Ub activity-based probe, Ub-vinyl sulfone.

    researchmap

  • iPS cell-based regeneration therapy for Alzheimer's disease.

    Grant number:22790092  2010 - 2011

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    MARUYAMA Masato

      More details

    Grant amount:\3380000 ( Direct expense: \2600000 、 Indirect expense:\780000 )

    There is no curative treatment for Alzheimer's diseases characterized by neuronal degeneration. To apply iPS cells to Alzheimer's disease, we established a method for efficient purification of neural stem cells derived from mouse iPS cells.

    researchmap

  • Elucidation of physiological role of Laeverin, a novel aminopeptidase.

    Grant number:20790088  2008 - 2009

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    MARUYAMA Masato

      More details

    Grant amount:\4290000 ( Direct expense: \3300000 、 Indirect expense:\990000 )

    Here, we evaluated the roles of His^<379>, comprising the exopeptidase motif, in the enzymatic properties of human Laeverin. Our results indicate that His^<379> plays essential roles in its distinctive enzymatic properties and contributes to maintaining the appropriate structure of the catalytic cavity of the enzyme.

    researchmap

  • Mechanisms of Enzymatic Action of the Oxytocinase Subfamily of Aminopeptidases

    Grant number:18390031  2006 - 2008

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    TSUJIMOTO Masafumi, HATTORI Akira, MARUYAMA Masato, GOTO Yoshikuni

      More details

    Grant amount:\17700000 ( Direct expense: \15300000 、 Indirect expense:\2400000 )

    本研究において私たちは妊娠の維持、記憶の維持、血圧調節、ガン細胞の増殖制御、抗原ペプチドのプロセシングなどその生理的/病理的重要性が明らかとなってきたオキシトシナーゼサブファミリーを含むM1アミノペプチダーゼ酵素の反応を点変異体を用いて解析し、M1酵素の基質特異性を決定している残基を同定することに成功した。これらの成果はM1酵素の反応機構および基質結合部位の構造を解明し、M1酵素を標的する医薬品を開発するうえで重要な知見を与えると考えられる。

    researchmap

  • アンギオテンシンIV受容体の細胞内ダイナミクスとその分子機構の解明

    2005.04 - 2007.03

    若手研究(B)

    丸山 正人

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3500000 ( Direct expense: \3500000 )

    researchmap

  • アンギオテンシンIV受容体の細胞内ダイナミクスとその分子機構の解明

    Grant number:17790080  2005 - 2006

    日本学術振興会  科学研究費助成事業 若手研究(B)  若手研究(B)

    丸山 正人

      More details

    Grant amount:\3500000 ( Direct expense: \3500000 )

    学習・記憶改善作用を示すアンギオテンシン(Ang)IVは、特異的な受容体である胎盤性ロイシンアミノペプチダーゼ(P-LAP)を介して作用を発揮することが知られている。P-LAPは細胞内小胞に存在し、脂肪細胞ではインスリン刺激により細胞膜へと移行することが知られているが、神経細胞での膜移行を誘導する生理的因子は全く不明である。そこで本年度は、膜表面ビオチン化法を用いて神経細胞におけるP-LAPの膜移行を惹起するペプチドホルモンを探索した。その結果、サブスタンスP(SP)で刺激した細胞では、SPの濃度及び時間依存的に細胞膜表面P-LAP量が増加することを明らかにした。脂肪細胞では、インスリン刺激によりP-LAPが細胞膜へと移行するが、SP刺激では細胞膜移行が見られなかったこと、また神経細胞では、インスリン刺激による膜表面P-LAP量の増加が認められなかったことから、見出した現象が神経細胞において特異的な現象であることを明らかにした。また、SPはcAMPをセカンドメッセンジャーとして細胞内にシグナルを伝達することが知られているため、細胞外にcAMPを処理した際のP-LAP膜移行について検討した。その結果、cAMPが細胞膜P-LAP量を有意に上昇させる現象が観察されたため、以上の結果と併せて、SPが細胞内cAMPを介して情報伝達されることにより、AngIV受容体の細胞膜移行を促進させ、膜表面上に増加したAngIV受容体が、AngIVの生理作用を増強する可能性が示された。これらの成果を、第11回病態と治療におけるプロテアーゼとインヒビター研究会(ポスター奨励賞受賞)、第28回生体膜と薬物の相互作用シンポジウム、RIKEN International symposium on chemical biology,において発表した。

    researchmap

▼display all

 

Class subject in charge

  • Introduction to Drug Research (2023academic year) Second semester  - 月3~4

  • Advanced Seminars in Drug Discovery and Drug Development (Pharmacokinetic analysis of drug metabolism and disposition) (2023academic year) special  - その他

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Life Science and Clinical Pharmaceutical Science (2023academic year) special  - その他

  • Life Science 3 (2023academic year) special  - その他

  • Pharmaceutics (2023academic year) 1st and 2nd semester  - 月1~2

  • Pharmaceutics (2023academic year) 1st and 2nd semester  - 月1~2

  • Pharmaceutics 1 (2023academic year) 1st semester  - 月1~2

  • Pharmaceutics 1 (2023academic year) 1st semester  - 月1~2

  • Pharmaceutics 2 (2023academic year) Second semester  - 月1~2

  • Pharmaceutics 2 (2023academic year) Second semester  - 月1~2

  • Introduction to Pharmaceutical Research (2023academic year) special  - その他

  • Introduction to Pharmaceutical Research (2023academic year) special  - その他

  • Introduction to Pharmaceutical Research (2023academic year) special  - その他

  • Introduction to Pharmaceutical Research (2023academic year) special  - その他

  • Advanced Lectures: Regulation and evaluation of pharmacokinetics (2023academic year) special  - その他

  • Pharmacokinetic analysis of drug metabolism and disposition (2023academic year) special  - その他

  • Pharmacokinetic analysis of drug metabolism and disposition (2023academic year) special  - その他

  • Seminor on pharmacokinetics (2023academic year) special  - その他

  • Pharmaceutical Manufacturing Sciences (2023academic year) 3rd and 4th semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences (2023academic year) 3rd and 4th semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 1 (2023academic year) Third semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 1 (2023academic year) Third semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 2 (2023academic year) Fourth semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 2 (2023academic year) Fourth semester  - 木3~4

  • Introduction to Drug Research (2022academic year) Second semester  - 月3~4

  • Practice in Clinical and Biopharmaceutical Sciences (2022academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2022academic year) Third semester  - その他5~9

  • Life Science 3 (2022academic year) special  - その他

  • Pharmaceutics (2022academic year) 1st and 2nd semester  - 月1~2

  • Pharmaceutics (2022academic year) 1st and 2nd semester  - 月1~2

  • Pharmaceutics 1 (2022academic year) 1st semester  - 月1~2

  • Pharmaceutics 1 (2022academic year) 1st semester  - 月1~2

  • Pharmaceutics 2 (2022academic year) Second semester  - 月1~2

  • Pharmaceutics 2 (2022academic year) Second semester  - 月1~2

  • Introduction to Pharmaceutical Research (2022academic year) special  - その他

  • Introduction to Pharmaceutical Research (2022academic year) special  - その他

  • Introduction to Pharmaceutical Research (2022academic year) special  - その他

  • Introduction to Pharmaceutical Research (2022academic year) special  - その他

  • Pharmacokinetic analysis of drug metabolism and disposition (2022academic year) special  - その他

  • Seminor on pharmacokinetics (2022academic year) special  - その他

  • Pharmaceutical Manufacturing Sciences (2022academic year) 3rd and 4th semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences (2022academic year) 3rd and 4th semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 1 (2022academic year) Third semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 1 (2022academic year) Third semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 2 (2022academic year) Fourth semester  - 木3~4

  • Pharmaceutical Manufacturing Sciences 2 (2022academic year) Fourth semester  - 木3~4

  • Introduction to Drug Research (2021academic year) Second semester  - 月3~4

  • Practice in Clinical and Biopharmaceutical Sciences (2021academic year) Third semester  - その他6~9

  • Practice in Clinical and Biopharmaceutical Sciences (2021academic year) Third semester  - その他6~9

  • Life Science 3 (2021academic year) Late  - その他

  • Pharmaceutics 1 (2021academic year) 1st semester  - 月1,月2

  • Pharmaceutics 1 (2021academic year) 1st semester  - 月1,月2

  • Pharmaceutics 2 (2021academic year) Second semester  - 月1,月2

  • Pharmaceutics 2 (2021academic year) Second semester  - 月1,月2

  • Basic Practice in Pharmaceutical Sciences (2021academic year) 1-3 semesters  - その他6~9

  • Basic Practice in Pharmaceutical Sciences (2021academic year) 1-3 semesters  - その他6~9

  • Introduction to Pharmaceutical Research (2021academic year) special  - その他

  • Introduction to Pharmaceutical Research (2021academic year) special  - その他

  • Introduction to Pharmaceutical Research (2021academic year) special  - その他

  • Introduction to Pharmaceutical Research (2021academic year) special  - その他

  • Pharmacokinetic analysis of drug metabolism and disposition (2021academic year) special  - その他

  • Seminor on pharmacokinetics (2021academic year) special  - その他

  • Practice in Clinical and Biopharmaceutical Sciences (2020academic year) Third semester  - その他

  • Practice in Clinical and Biopharmaceutical Sciences (2020academic year) Third semester  - その他

  • Life Science 3 (2020academic year) special  - その他

  • Pharmaceutics 1 (2020academic year) 1st semester  - 月1,月2

  • Pharmaceutics 1 (2020academic year) 1st semester  - 月1,月2

  • Pharmaceutics 2 (2020academic year) Second semester  - 月1,月2

  • Pharmaceutics 2 (2020academic year) Second semester  - 月1,月2

  • Basic Practice in Pharmaceutical Sciences (2020academic year) special  - その他

  • Basic Practice in Pharmaceutical Sciences (2020academic year) special  - その他

  • Pharmacokinetic analysis of drug metabolism and disposition (2020academic year) special  - その他

▼display all